MODERN TREATMENT WITH TERIPARATIDE IN PATIENTS WITH SEVERE OSTEOPOROSIS
Abstract:
Teriparatide is the first anabolic agent to stimulate osteoblastic bone formation and improve bone mass and quality. A total of 26 patients with severe osteoporosis were studied, in whom treatment with Teriparatide was initiated, with re-evaluation in the first and second year of therapy. Patients in our study have various levels of 25-hydroxy-vitamin D. In the selected subgroup, an increase in bone mineral density was observed in the first year of therapy. Regarding T-score and Z-score, there was an increase in the first year. An increase of Beta-CrossLaps levels in the first year and then a decrease at the end of therapy in the second year was observed. An increase of osteocalcin levels was observed in the first year, diminished later. Treatment with Teriparatide is generally well tolerated and patients claim significant improvement in the quality of life.
full text article in English (.EN) |